Global & Regional Health Technology Assessment最新文献

{"title":"A multicriteria decision analysis (MCDA) applied to three long-term prophylactic treatments for hereditary angioedema in Spain.","authors":"Néboa Zozaya,&nbsp;Teresa Caballero,&nbsp;Teresa González-Quevedo,&nbsp;Pedro Gamboa Setien,&nbsp;Mª Ángeles González,&nbsp;Ramón Jódar,&nbsp;José Luis Poveda-Andrés,&nbsp;Encarna Guillén-Navarro,&nbsp;Agustín Rivero Cuadrado,&nbsp;Álvaro Hidalgo-Vega","doi":"10.33393/grhta.2022.2333","DOIUrl":"https://doi.org/10.33393/grhta.2022.2333","url":null,"abstract":"<p><strong>Introduction: </strong>Hereditary angioedema (HAE) is a rare genetic disease that impairs quality of life and could be life-threatening. The aim of this study was to apply a multicriteria decision analysis to assess the value of three long-term prophylactic (LTP) therapies for HAE in Spain.</p><p><strong>Methods: </strong>A multidisciplinary committee of 10 experts assessed the value of lanadelumab (subcutaneous use), C1-inhibitor (C1-INH; intravenous), and danazol (orally), using placebo as comparator. We followed the EVIDEM methodology that considers a set of 13 quantitative criteria. The overall estimated value of each intervention was obtained combining the weighting of each criterion with the scoring of each intervention in each criterion. We used two alternative weighting methods: hierarchical point allocation (HPA) and direct rating scale (DRS). A reevaluation of weightings and scores was performed.</p><p><strong>Results: </strong>Lanadelumab obtained higher mean scores than C1-INH and danazol in all criteria, except for the cost of the intervention and clinical practice guidelines. Under the HPA method, the estimated values were 0.51 (95% confidence interval [CI]: 0.44-0.58) for lanadelumab, 0.47 (95%CI: 0.41-0.53) for C1-INH, and 0.31 (95%CI: 0.24-0.39) for danazol. Similar results were obtained with the DRS method: 0.51 (95%CI: 0.42-0.60), 0.47 (95%CI: 0.40-0.54), and 0.27 (95%CI: 0.18-0.37), respectively. The comparative cost of the intervention was the only criterion that contributed negatively to the values of lanadelumab and C1-INH. For danazol, four criteria contributed negatively, mainly comparative safety.</p><p><strong>Conclusion: </strong>Lanadelumab was assessed as a high-value intervention, better than C1-INH and substantially better than danazol for LTP treatment of HAE.</p>","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e3/ad/grhta-9-14.PMC9768612.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9084274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dieci priorità nel trattamento del paziente con sindrome coronarica acuta.","authors":"Giovanni Esposito,&nbsp;Fabrizio Ricci,&nbsp;Giovanni Battista Zito","doi":"10.33393/grhta.2022.2392","DOIUrl":"https://doi.org/10.33393/grhta.2022.2392","url":null,"abstract":"Ten priorities in the treatment of the ACS patient From the topics addressed in the articles of this Special Issue, dedicated to acute coronary syndromes (ACS), some priorities have emerged summarizing the complexity of the management of these patients, which must take into account not only clinical and pharmacological factors but also logistical and organizational aspects, as well as elements of health policy. Only the synergy between these different aspects can bring out the solution for the optimization of ACS management, in terms of prevention, diagnosis, treatment and improvement of the patient's quality of life.","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/39/5a/grhta-9-S1-27.PMC9796601.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10513775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analisi di costo-utilità di ceftolozano/tazobactam rispetto a meropenem in pazienti con polmonite acquisita in ospedale (HABP) o polmonite associata a ventilazione meccanica (VABP).","authors":"Francesco Saverio Mennini,&nbsp;Martina Paoletti,&nbsp;Chiara Bini,&nbsp;Andrea Marcellusi,&nbsp;Marco Falcone,&nbsp;Massimo Andreoni","doi":"10.33393/grhta.2022.2287","DOIUrl":"https://doi.org/10.33393/grhta.2022.2287","url":null,"abstract":"Cost-utility analysis of ceftolozane/tazobactam vs meropenem in patients with hospital-acquired pneumonia (HABP) or ventilator-associated pneumonia (VABP) Objective: This study aims to evaluate the cost-effectiveness of ceftolozane/tazobactam compared to meropenem for the treatment of patients with hospital-acquired pneumonia (HABP) or ventilator-associated pneumonia (VABP) from the Italian National Health Service (NHS) and social perspective. Method: A decision tree and a Markov model were developed in order to forecast long-term and short-term disease effects respectively. A hypothetical target population of 1,000 HABP/VABP patients was followed for a lifetime time horizon. In the short-term decision tree, two different settings were developed in order to evaluate the value of empirical therapy compared with the start of treatment after confirmation of the antibiogram. Treated and cured patients enter the long-term Markov model following the mortality of the general population. Direct and indirect costs were considered accordingly with the analysis perspective. Results: The analysis showed that ceftolozane/tazobactam, in both treatment settings (empirical and confirmed), may be a cost-effective option compared to meropenem from the NHS and social perspective (ICER equal to € 1,913 and € 2,203 in the empirical treatment setting and € 6,163 and € 6,597 in the confirmed treatment setting for NHS and social perspective respectively). Conclusions: Introduction of ceftolozane/tazobactam within the Italian healthcare context can represent a valid therapeutic solution both from an economic and an efficacy profile point of view.","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/41/34/grhta-9-45.PMC9768596.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10518584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gestione del paziente con sindrome coronarica acuta.","authors":"Giovanni Esposito,&nbsp;Fabrizio Ricci,&nbsp;Giovanni Battista Zito","doi":"10.33393/grhta.2022.2388","DOIUrl":"https://doi.org/10.33393/grhta.2022.2388","url":null,"abstract":"","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a4/9a/grhta-9-S1-1.PMC9796594.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10513776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"La gestione a lungo termine del paziente a rischio: territorio e ospedale, ruolo e sinergie.","authors":"Giovanni Battista Zito","doi":"10.33393/grhta.2022.2390","DOIUrl":"https://doi.org/10.33393/grhta.2022.2390","url":null,"abstract":"Long-term management of the patient at risk: outpatient clinic and hospital, role and synergies Cardiovascular and cerebrovascular diseases are the main cause of death worldwide. In particular, ischemic heart disease is associated with increased mortality risk and decreased quality of life. Population aging is going to increase the overall prevalence of cardiovascular diseases, which is strictly age-related, with a growing economic burden on health systems and society. Effective intervention strategies to control modifiable risk factors for cardiovascular diseases and thereby to reduce the incidence of new events are crucial to limit the huge impact of such diseases on health and quality of life. A strict collaboration between hospitals, where acute events are managed, and outpatient clinics, where patients are followed in the long-term, is the starting point to optimize treatment and secondary prevention, improving adherence to therapy and patient satisfaction.","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5d/54/grhta-9-S1-14.PMC9796595.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10520263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and economic consequences of ozenoxacin vs. other topical antibiotics for the treatment of impetigo: a real-life study in Spain.","authors":"Jaime Rodríguez-Quintosa,&nbsp;Cintia Cristina Ago,&nbsp;Antoni Sicras-Mainar,&nbsp;Renata Villoro,&nbsp;Inés Pérez-Román","doi":"10.33393/grhta.2022.2439","DOIUrl":"https://doi.org/10.33393/grhta.2022.2439","url":null,"abstract":"<p><strong>Background: </strong>Impetigo is a common dermatological paediatric infection that can be treated with topical antibiotics: the common are mupirocin (MUP), fusidic acid (FA) and, most recently, ozenoxacin (OZ).</p><p><strong>Aim: </strong>This study assesses the clinical and economic consequences of the use of OZ vs. MUP and vs. FA for the treatment of impetigo in routine clinical practice in Spain.</p><p><strong>Methods: </strong>This is a retrospective observational study using real-life data from electronic medical records of patients with impetigo who started treatment with OZ, MUP or FA (maximum follow-up: 3 months; n = 10,974). We compared treatment duration, comorbidities, use of systemic medication, complications, utilization of resources and associated costs across treatments (p<0.05). Cost-effectiveness of OZ was assessed from a social perspective. Complication rates and treatment duration were the effectiveness measures.</p><p><strong>Results: </strong>Mean age was 12.6 (standard deviation [SD]: 16.6) years; 48.6% were male; treatment: 9.3% (OZ), 56.4% (MUP), 34.5% (FA). The percentage of patients ending treatment after 2 weeks was 87.6% (OZ) vs. 83.2% (MUP) vs. 82.4% (FA); p<0.001; complication rates were 1.8% (OZ), 3.3% (MUP) and 3.2% (FA), p<0.001; mean costs were €158 (OZ), €265 (MUP) and €287 (FA), p<0.001.</p><p><strong>Conclusions: </strong>OZ is a cost-effective and dominant alternative for the treatment of impetigo.</p>","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/67/f4/grhta-9-133.PMC9616209.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10521001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analisi di impatto di budget di un nuovo sistema di cura in pazienti affetti da malattia di Parkinson.","authors":"Chiara Bini,&nbsp;Francesco Saverio Mennini,&nbsp;Andrea Marcellusi,&nbsp;Martina Paoletti,&nbsp;Carlo Tomino","doi":"10.33393/grhta.2022.2413","DOIUrl":"https://doi.org/10.33393/grhta.2022.2413","url":null,"abstract":"Objective: To estimate the economic impact of the introduction of a new care system based on apomorphine and Patient Support Program for motor fluctuations (“on-off” phenomena) in patients with Parkinson’s disease which are not sufficiently controlled by oral anti-Parkinson medication in Italy.\u0000Method: A Budget Impact model was developed to evaluate the new care system in patients with Parkinson’s disease over a 3-years’ time horizon. The comparator treatments included in the analysis were treatments based on apomorphine and levodopa + carbidopa. The analysis was conducted from a National Health Service (NHS) perspective. Costs included in the analysis were acquisition costs and device costs. A deterministic sensitivity analysis was carried out to evaluate the uncertainty of the parameters used. A break-even analysis was conducted to identify the minimum number of subjects that would need to be treated with the new care system to obtain a positive Budget Impact (World With – World Without = 0).\u0000Results: The analysis shows that the introduction of the new care system based on apomorphine could generate a cost saving incurred by the NHS of over € 5.7 million in 3 years. Break-even analysis shows that if it were possible to intercept with the new treatment at least 9 patients treated with apomorphine, there would not be an increase in costs for the NHS.\u0000Conclusion: The new care system would respond to the unmet needs of patients with Parkinson’s disease by generating a reduction in the expenditure incurred by NHS.","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/da/5b/grhta-9-91.PMC9768609.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10518583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of a maturity model for facilitating the introduction of CAR T-cell therapy-Results of the START CAR-T project.","authors":"Stefania Bramanti,&nbsp;Matteo G Carrabba,&nbsp;Alice Di Rocco,&nbsp;Elena Fabris,&nbsp;Luca Gastaldi,&nbsp;Paolo Locatelli,&nbsp;Maria Chiara Tisi","doi":"10.33393/grhta.2022.2340","DOIUrl":"https://doi.org/10.33393/grhta.2022.2340","url":null,"abstract":"<p><strong>Introduction: </strong>Chimeric antigen receptor (CAR) T-cell therapies are novel immunotherapies for the treatment of hematologic malignancies. They are administered in specialized centers by a multidisciplinary team and require the careful coordination of all steps involved in manufacturing and using cellular therapies. The Maturity Model (MM) is a tool developed and used for assessing the effectiveness of a variety of activities. In healthcare, it may assist clinicians in the gradual improvement of patient management with CAR T-cell therapy and other complex treatments.</p><p><strong>Methods: </strong>The START CAR-T project was initiated to investigate the potential of a MM in the setting of CAR T-cell therapy. Four Italian clinics participated in the creation of a dedicated MM. Following the development and test of this MM, its validity and generalizability were further tested with a questionnaire submitted to 18 Italian centers.</p><p><strong>Results: </strong>The START CAR-T MM assessed the maturity level of clinical sites, with a focus on organization, process, and digital support. For each area, the model defined four maturity steps, and indicated the actions required to evolve from a basic to an advanced status. The application of the MM to 18 clinical sites provided a description of the maturity level of Italian centers with regard to the introduction of CAR T-cell therapy.</p><p><strong>Conclusion: </strong>The START CAR-T MM appears to be a useful and widely applicable tool. It may help centers optimize many aspects of CAR T-cell therapy and improve patient access to this novel treatment option.</p>","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4d/43/grhta-9-1.PMC9768606.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10525353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regolazione del prezzo e rimborso dei farmaci: comparatori, endpoint e ruolo della costo-efficacia.","authors":"Claudio Jommi,&nbsp;Giovanni Apolone,&nbsp;Giovanna Scroccaro,&nbsp;Valentina Acciai,&nbsp;Antonio Addis,&nbsp;Andrea Ardizzoni,&nbsp;Renato Bernardini,&nbsp;Alberto Bortolami,&nbsp;Alessia Brigido,&nbsp;Giuliano Buzzetti,&nbsp;Pier Luigi Canonico,&nbsp;Francesca Caprari,&nbsp;Stefano Centanni,&nbsp;Chiara Cernetti,&nbsp;Americo Cicchetti,&nbsp;Giorgio Corsico,&nbsp;Francesco Damele,&nbsp;Filippo de Braud,&nbsp;Sara Manurita,&nbsp;Francesco Saverio Mennini,&nbsp;Irene Olivi,&nbsp;Federica Parretta,&nbsp;Lara Pippo,&nbsp;Stefania Pulimeno,&nbsp;Massimo Riccaboni,&nbsp;Giuseppe Rossi,&nbsp;Cecilia Saleri,&nbsp;Alessandra Sinibaldi,&nbsp;Federico Spandonaro,&nbsp;Cristian Stefenoni,&nbsp;Elena Visentin,&nbsp;Pierluigi Viale,&nbsp;Giuseppina Zapparelli,&nbsp;Patrizia Popoli","doi":"10.33393/grhta.2022.2475","DOIUrl":"https://doi.org/10.33393/grhta.2022.2475","url":null,"abstract":"This document illustrates the results of a discussion of two multi-disciplinary expert panels on pricing and reimbursement of medicines. Experts work in different organizations. The discussion focused on comparator(s), endpoint(s), negotiation of prices of new medicines and/or indications to include in the List 648, as well as the role of cost-effectiveness in the price and reimbursement negotiation. The debate took place during the fourth edition of the Seminari di Mogliano, organized on the 30th of September/1st of October, 2021.\u0000The two panels agreed on a general need to enhance interaction among the different stakeholders, in the early assessment and negotiation phases, and to increase the transparency/reproducibility of the decisions taken. The experts have also emphasized the need (i) to improve clarity in the evaluation of additional therapeutic value and the place in therapy with respect to comparators and how comparators are identified; (ii) to create work groups to identify the most appropriate endpoint(s), for each therapeutic area and level of unmet needs; (iii) to provide for a systematic use of cost-effectiveness when an added therapeutic value is delivered by a new medicine. With regard to the 648 List, the experts advocated for an overall reorganization of the current rules governing the special uses of drugs.","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4d/94/grhta-9-99.PMC9768592.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10520998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Budget impact analysis sull’introduzione del dispositivo di telemonitoraggio Turbo+ nella gestione dei pazienti asmatici in Italia.","authors":"Filippo Rumi,&nbsp;Michele Basile,&nbsp;Americo Cicchetti,&nbsp;Rosario Contiguglia,&nbsp;Antonella Pentassuglia,&nbsp;Alessandro Oliva,&nbsp;Gianenrico Senna,&nbsp;Marco Bonavia,&nbsp;Francesco Scarpelli,&nbsp;Marco Benvenuto","doi":"10.33393/grhta.2022.2290","DOIUrl":"https://doi.org/10.33393/grhta.2022.2290","url":null,"abstract":"Introduction of the telemonitoring device Turbo+ in the management of patients suffering from asthma in Italy: a budget impact analysis Introduction: Adherence to long-term asthma control drugs is one of the key factors in improving disease management among patients with asthma. Poor adherence to long-term therapies significantly compromises the effectiveness of treatment and represents a problem in controlling the disease in terms of quality of life and economic impact. A budget impact analysis has been developed taking into account that Turbo+ technology (electronic monitoring device) can increase adherence to therapy in patients suffering from asthma. Methods: Coherently with the budget impact model methodology, we developed two different scenarios. One represents the clinical practice assuming a constant market share of 0,99% for Turbo+ and the other one assumes an incremental market share of Turbo+ over the time horizon considered. An increase in adherence to therapy will likely correspond to a reduction of exacerbations and a lower rate of hospitalizations, thus generating savings in terms of use of health resources. Results: The differential analysis shows an incremental saving in terms of resources absorbed by the National Health Service (NHS) over the time horizon considered. In the first year the savings are equal to € 795,658.64 and in the fifth year they are equal to € 3,520,636.34 for a total of resources saved in 5 years of € 10,882,028.50. Conclusions: The model shows how the diffusion of the Turbo+ programme can lead to savings in terms of health resources consumed by the NHS. Further analyses with new real-world data on adherence in asthmatic patients could be useful in confirming the results of the present analysis.","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/dc/83/grhta-9-58.PMC9768613.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10511649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}